Inviga Healthcare Fund (IHF), founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health. Forus Health is an Indian ophthalmic diagnostics company whose devices have screened over 22 million patients across more than 75 countries. The company’s digital platform integrated with AI for Ocular and Oculomics has delivered comprehensive eye diagnostics to more than five million patients globally.
The secondary transaction indicates Inviga Healthcare Fund’s intent to support AI-based diagnostic solutions developed in India and deployed in international markets. This is Inviga’s second major investment, following its investment in Mynvax in 2024.
Dr B. S. Ajaikumar, Founder, Inviga Healthcare Fund and Chairman, HCG, said, “Forus Health embodies the Inviga ethos: clinically strong, technologically deep, socially impactful, growth oriented, profitable. This investment is a testament to our confidence in India’s ability to produce world-class healthcare innovations for domestic and international markets. We are delighted to partner with visionary founders like Chandrasekhar (KC) who combine deep insight with execution to make preventive, equitable healthcare a reality.”
- Chandrasekhar, Co-founder and CEO, Forus Health, said, “We are thrilled to welcome Inviga as we enter the next phase of our growth. Their expertise in healthcare, operational experience, and insights from a clinician’s perspective are incredibly valuable. Together, we aim to enhance our AI and platform capabilities, utilise our proven ability to innovate in medical devices, and expand our reach both in India and globally. Our mission remains focused on eradicating preventable blindness.”
Inviga Healthcare Fund invests in healthcare ventures and supports Indian healthcare entrepreneurship. Its approach focuses on building sustainable and outcome-focused healthcare platforms.
Forus Health was founded by K. Chandrasekhar. The company is known for its 3nethra series of ophthalmic screening devices, used globally to improve access to vision care. In 2025, Forus Health was listed among TIME Magazine’s World’s Top 400 HealthTech Companies. The company offers a digital platform for managing eye health. Its product, 3nethra specto, is described as a wearable digital refractor operated via smartphone to support remote and tele-optometry services.
Rakshith Rangarajan, Fund Manager, Inviga Healthcare Fund, said, “Our collaboration with Forus is a strategic step intended to facilitate the expansion of a reputed med-tech franchise that is serving a significant market demand through a sustainable and economically sound business model. It reflects our commitment to advancing accessible solutions that address large, unsolved health challenges. The Make in India, Make for India and Make for the World ethos of Forus resonates deeply with our Fund. We’re confident this partnership will drive sustained growth and long-term value creation.”
The global burden of preventable blindness highlights the need for scalable eye-care solutions. It is estimated that more than 270 million people in India live with visual impairment, much of which is preventable. The presence of diabetes places one in five individuals at risk of diabetic retinopathy. Preterm births place infants at risk of retinopathy of prematurity. Globally, more than 2.2 billion people live with vision impairment or blindness, with more than one billion cases considered preventable or treatable. Forus Health’s devices support early-stage screening in both emerging and developed markets.
Inviga Healthcare Fund is developing a platform of multi-specialty hospitals while also investing in emerging healthcare and life sciences enterprises. The strategy includes hospital consolidation and minority investments in companies with intellectual property. The Fund aims to build healthcare enterprises that align clinical capabilities with scalable growth.